EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 644 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Inavolisib June 26, 2025 Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer November 5, 2019 NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials June 29, 2018 Reflections from our chief clinician: The essential role of our research... February 4, 2022 Load more HOT NEWS Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a... Physicians Debate Recent FDA Approval of an Immune Checkpoint Inhibitor in... How I Rebuilt My Self-Image After a Laryngectomy: A Cancer Survivor’s... The stories behind Teenage and Young Adult Cancer Awareness Month
